C07K 2317/515
Complete light chain, i.e. vl + cl
Official title: Complete light chain, i.e. VL + CL
C07K2317/515 (Complete light chain, i.e. vl + cl) appears on 1,285 US grants and 2,164 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,285
- Published applications
- 2,164
- Assignees
- 681
- Inventors
- 3,457
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 3 | 1 |
| 2003 | 1 | 2 |
| 2004 | 0 | 3 |
| 2005 | 0 | 4 |
| 2006 | 1 | 3 |
| 2007 | 1 | 5 |
| 2008 | 3 | 5 |
| 2009 | 1 | 22 |
| 2010 | 4 | 23 |
| 2011 | 10 | 40 |
| 2012 | 13 | 45 |
| 2013 | 31 | 75 |
| 2014 | 35 | 102 |
| 2015 | 65 | 116 |
| 2016 | 113 | 213 |
| 2017 | 95 | 211 |
| 2018 | 117 | 146 |
| 2019 | 115 | 169 |
| 2020 | 150 | 178 |
| 2021 | 105 | 191 |
| 2022 | 102 | 179 |
| 2023 | 92 | 122 |
| 2024 | 91 | 125 |
| 2025 | 90 | 113 |
| 2026 | 47 | 71 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- MICA/B antibodies and methods of use29 Sep 2026US 12,747,293 B2Cullinan Mica Corporation
- Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use15 Sep 2026US 12,735,497 B2Hoffmann-La Roche Inc.
- Anti-TIGIT antibody and double antibody and their application1 Sep 2026US 12,723,085 B2Nanjing Sanhome Pharmaceutical Co., Ltd.
- λ antibodies1 Sep 2026US 12,723,104 B2Kymab Limited
- Angiopoietin 2, VEGF dual antagonists25 Aug 2026US 12,715,912 B2AskGene Pharma Inc.
- Il-15 inhibitors useful for the treatment of atopic dermatitis1 Oct 2026US 2026/0297174 A1Novartis Pharma AG
- Methods and compositions comprising purified recombinant polypeptides1 Oct 2026US 2026/0297179 A1Genentech, Inc.
- Anti-HER2 Antibodies and Immunoconjugates1 Oct 2026US 2026/0297214 A1Genentech, Inc.
- Method for treating systemic lupus erythematosus24 Sep 2026US 2026/0285964 A1Huabo Biopharm (Shanghai) Co., Ltd.
- Multispecific antigen binding proteins and uses thereof10 Sep 2026US 2026/0265376 A1Itabmed Co., Ltd.
Most cited
By later US patents
- Methods of modifying eukaryotic cells420US 6,596,541 B2Regeneron Pharmaceuticals, Inc. · 2003
- Methods of modifying eukaryotic cells171US 8,502,018 B2Regeneron Pharmaceuticals, Inc. · 2013
- Antibodies with modified isoelectric points139US 8,637,641 B2Xencor, Inc. · 2014
- Protein purification135US 6,489,447 B1Genentech, Inc. · 2002
- Combination therapies employing GITR binding molecules129US 8,591,886 B2GITR, Inc. · 2013